COYA
COYA
NASDAQ · Biotechnology

Coya Therapeutics Inc

$4.98
-0.10 (-1.97%)
As of Sep 28, 10:22 PM ET ·
Financial Highlights (FY 2026)
Revenue
11.36M
Net Income
-30,346,819
Gross Margin
—
Profit Margin
-267.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 59.4% 59.4% 59.4%
Operating Margin -283.9% -21.4% -22.3% -21.3%
Profit Margin -267.1% -24.1% -19.2% -20.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 11.36M 21.48M 20.04M 21.53M
Gross Profit — 12.76M 11.90M 12.79M
Operating Income -32,246,002 -4,588,283 -4,466,509 -4,589,536
Net Income -30,346,819 -5,165,355 -3,853,498 -4,413,133
Gross Margin — 59.4% 59.4% 59.4%
Operating Margin -283.9% -21.4% -22.3% -21.3%
Profit Margin -267.1% -24.1% -19.2% -20.5%
Rev Growth — -8.7% +0.8% +4.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 20.03M 19.96M 21.21M
Total Equity — 82.70M 80.09M 74.44M
D/E Ratio — 0.24 0.25 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -32,207,765 -6,655,427 -5,995,002 -5,792,790
Free Cash Flow — -3,535,951 -2,421,928 -4,008,931